Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23355367 | 0.83 | KDM4E (0.34) | NPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL30203116 | 0.82 | NPC1 (0.47) | NPC1RAB9ACASP3POLBMGLL | |
| SCHEMBL23368156 | 0.82 | NPC1 (0.47) | NPC1RAB9ACASP3POLBMGLL | |
| SCHEMBL12992502 | 0.78 | NPC1 (0.44) | NPC1RAB9ACASP3POLBP2RX7 | |
| SCHEMBL23355405 | 0.77 | SMN1; SMN2 (0.39) | NPC1RAB9AMGLLSMN1; SMN2SCD | |
| SCHEMBL9427405 | 0.76 | NPC1 (0.49) | NPC1RAB9ACASP3POLBP2RX7 | |
| SCHEMBL30203299 | 0.75 | SMN1; SMN2 (0.38) | NPC1RAB9ASMN1; SMN2SCD | |
| SCHEMBL28537445 | 0.75 | TRPM8 (0.38) | NPC1RAB9A | |
| SCHEMBL8083786 | 0.75 | NPC1 (0.52) | NPC1RAB9ACASP3POLBP2RX7 | |
| SCHEMBL31569325 | 0.74 | NPC1 (0.61) | NPC1RAB9ACASP3POLBP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | ERBB2, EGFR, ERBB3 | NPC1 2118/4885RAB9A 667/4885CASP3 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.